Altimmune, Inc.
ALT
$5.33
$0.224.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | -13.20% | 8.90% | |||
| Gross Profit | 13.21% | -8.91% | |||
| SG&A Expenses | 3.74% | -5.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.00% | 5.07% | |||
| Operating Income | 9.00% | -5.07% | |||
| Income Before Tax | 14.14% | -9.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.14% | -13.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.14% | -13.13% | |||
| EBIT | 9.00% | -5.07% | |||
| EBITDA | 9.00% | -5.08% | |||
| EPS Basic | 21.78% | -4.90% | |||
| Normalized Basic EPS | 21.78% | -1.37% | |||
| EPS Diluted | 21.78% | -4.90% | |||
| Normalized Diluted EPS | 21.78% | -1.37% | |||
| Average Basic Shares Outstanding | 9.75% | 7.85% | |||
| Average Diluted Shares Outstanding | 9.75% | 7.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||